泌尿生殖藥物市場：按產品、適應症、藥物類型 - 全球預測 2023-2030

全球泌尿生殖藥物市場預計將大幅成長，預計到 2023 年將達到 383 億美元，年複合成長率為 4.11%，預計到 2030 年將達到驚人的 510.1 億美元。

FPNV定位矩陣

FPNV 定位矩陣對於評估全球泌尿生殖治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球泌尿生殖藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球泌尿生殖藥物市場的阻礙因素與影響為何？

3.預測期內全球泌尿生殖藥物市場需要投資哪些產品/細分市場/應用/領域？

4.貴公司在全球泌尿生殖藥物市場的競爭策略為何？

5. 全球泌尿生殖藥物市場的技術趨勢和法律規範是什麼？

6.全球泌尿生殖醫學市場主要廠商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入全球泌尿生殖藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 泌尿生殖系統疾病盛行率增加
    • 管道藥物數量增加
    • 人們越來越擔心尿失禁和陽痿
  • 抑制因素
    • 市面上有假藥和學名藥
  • 機會
    • 製藥公司聯合研發
    • 增加醫療保健投資以改善治療方法
  • 任務
    • 缺乏合規性
    • 連續專利到期
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 泌尿生殖藥物市場：副產品

• 感染疾病
• 婦科
• 荷爾蒙治療
• 泌尿系統

第7章 依適應症分列的泌尿生殖藥物市場

• 良性攝護腺增生症
• 膀胱癌
• 子宮頸癌
• 勃起功能障礙
• 血尿
• 間質性膀胱炎
• 卵巢癌
• 攝護腺癌
• 腎癌
• 性感染疾病
• 尿失禁和膀胱過動症
• 泌尿道感染疾病

第8章 按藥物類型分類的泌尿生殖藥物市場

• 荷爾蒙治療
• 壯陽劑
• 尿路解痙藥
• 尿液pH調節劑
• 子宮鬆弛劑
• 子宮興奮劑

第9章 美洲泌尿生殖藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太泌尿生殖藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東及非洲泌尿生殖醫學市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Genitourinary Drugs Market is forecasted to grow significantly, with a projected USD 38.30 billion in 2023 at a CAGR of 4.11% and expected to reach a staggering USD 51.01 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Genitourinary Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Genitourinary Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Anti-infectives, Gynecological, Hormonal Therapy, and Urologicals. The Urologicals is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer, Erectile Dysfunction, Hematuria, Interstitial Cystitis, Ovarian Cancer, Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Urinary Incontinence & Overactive Bladder, and Urinary Tract Infections. The Urinary Incontinence & Overactive Bladder is projected to witness significant market share during forecast period.

Based on Drug Type, market is studied across Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, and Uterine Stimulants. The Uterine Relaxants is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 34.87% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Genitourinary Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Genitourinary Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Genitourinary Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Genitourinary Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Genitourinary Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Genitourinary Drugs Market?

6. What is the market share of the leading vendors in the Global Genitourinary Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Genitourinary Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Genitourinary Drugs Market, by Product, 2022 vs 2030
• 4.3. Genitourinary Drugs Market, by Indication, 2022 vs 2030
• 4.4. Genitourinary Drugs Market, by Drug Type, 2022 vs 2030
• 4.5. Genitourinary Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genitourinary disorders
    • 5.1.1.2. Rising number of pipeline drugs
    • 5.1.1.3. Growing concerns about urinary incontinence and impotence
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of counterfeit and generics drugs in the market
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative R&D efforts by the pharma companies
    • 5.1.3.2. Growing investment in healthcare for improved treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of compliance to medication
    • 5.1.4.2. Continual patent expirations
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Genitourinary Drugs Market, by Product

• 6.1. Introduction
• 6.2. Anti-infectives
• 6.3. Gynecological
• 6.4. Hormonal Therapy
• 6.5. Urologicals

7. Genitourinary Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Benign Prostatic Hyperplasia
• 7.3. Bladder Cancer
• 7.4. Cervical Cancer
• 7.5. Erectile Dysfunction
• 7.6. Hematuria
• 7.7. Interstitial Cystitis
• 7.8. Ovarian Cancer
• 7.9. Prostate Cancer
• 7.10. Renal Cancer
• 7.11. Sexually Transmitted Diseases
• 7.12. Urinary Incontinence & Overactive Bladder
• 7.13. Urinary Tract Infections

8. Genitourinary Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Hormonal Therapy
• 8.3. Impotence Agents
• 8.4. Urinary Antispasmodics
• 8.5. Urinary pH Modifiers
• 8.6. Uterine Relaxants
• 8.7. Uterine Stimulants

9. Americas Genitourinary Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Genitourinary Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Genitourinary Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 5. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 6. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
• FIGURE 7. GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. GENITOURINARY DRUGS MARKET DYNAMICS
• FIGURE 9. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 5. GENITOURINARY DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. GENITOURINARY DRUGS MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. GENITOURINARY DRUGS MARKET SIZE, BY UROLOGICALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 10. GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GENITOURINARY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GENITOURINARY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GENITOURINARY DRUGS MARKET SIZE, BY HEMATURIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GENITOURINARY DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GENITOURINARY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GENITOURINARY DRUGS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GENITOURINARY DRUGS MARKET SIZE, BY URINARY INCONTINENCE & OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GENITOURINARY DRUGS MARKET SIZE, BY IMPOTENCE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GENITOURINARY DRUGS MARKET SIZE, BY URINARY ANTISPASMODICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GENITOURINARY DRUGS MARKET SIZE, BY URINARY PH MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GENITOURINARY DRUGS MARKET SIZE, BY UTERINE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GENITOURINARY DRUGS MARKET SIZE, BY UTERINE STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. INDIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. INDIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ITALY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. ITALY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. ITALY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. POLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. POLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. POLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. QATAR GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. QATAR GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. QATAR GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 157. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 158. GENITOURINARY DRUGS MARKET LICENSE & PRICING